Close

Pfizer buys Swiss preclinical stage firm Redvax

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Pfizer has purchased a controlling stake in Redvax, a spin-off from Swiss biopharmaceutical firm Redbiotec.

Terms of the transaction were not disclosed.

Redvax is a preclinical stage company, which develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of cytomegalovirus (CMV) and a further undisclosed field.

Pfizer senior vice-president of vaccine research and early development Kathrin Jansen said: “Through the acquisition of the Redvax innovative CMV vaccine platform and expertise, we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children.”

The deal allows Pfizer to gain access to a preclinical human CMV vaccine candidate, in addition to intellectual property and a technology platform related to a second, undisclosed vaccine programme.

The CMV vaccine programme is said to be in line with Pfizer’s portfolio of investigational vaccines, while CMV is a herpes virus, infecting 50%-90% of the adult population, with a majority remaining asymptomatic.

Redbiotec CEO and Redvax managing director Christian Schaub said: “We are pleased to have completed this deal with Pfizer, a global leader in vaccines.

“This represents an important step toward the development of a much needed vaccine for CMV, a disease that has a devastating impact on children and families.”

According to US Centres for Disease Control and Prevention (CDC), 5,000 children each year develop health problems caused by CMV such as hearing or vision loss and mental disability.

 

Latest stories

Related stories

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Cook Medical Says Extra Tariff to Be Passed to US Customers

According to medical device firm Cook Medical, the costs...

FDA Aims to Decrease Animal Testing as Tech Gathers Pace

Drug developers are raising the adoption of AI technologies...

$2 Billion Expansion By J&J in North Carolina Facility

Johnson & Johnson on August 21, 2025, went on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back